Data for ENMD-2076 Phase 1 Studies in Leukemia and Multiple Myeloma Presented at ASH

Data for ENMD-2076 Phase 1 Studies in Leukemia and Multiple Myeloma Presented at ASH EntreMed, Inc.. , Announced today the presentation of data for ITS Phase 2 oncology drug candidate, ENMD-2076 an Aurora A / angiogenic kinase inhibitor. ? Data from the Phase 1 studies with ENMD-2076 in patient with multiple myeloma and relapsed or refractory leukemia Were presented by EntreMed investigators consistently poster sessions at the 2010 American Society of Hematology Annual Meeting being … Read more on PR Newswire via Yahoo Finance

view more about our orlando web development services here.

Tags: , , , , , , ,

Comments are closed.